138 related articles for article (PubMed ID: 38044241)
1. Infection outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Skovron ML; Frisell T; Askling J; Michaud K; Pedro S; Strangfeld A; Meissner Y; Boers M; Hoffman V; Dominique A; Gomez A; Hochberg MC
Semin Arthritis Rheum; 2024 Feb; 64():152313. PubMed ID: 38044241
[TBL] [Abstract][Full Text] [Related]
2. Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study.
Simon TA; Suissa S; Boers M; Hochberg MC; Skovron ML; Askling J; Michaud K; Strangfeld A; Pedro S; Frisell T; Meissner Y; Dominique A; Gomez A
Semin Arthritis Rheum; 2024 Feb; 64():152240. PubMed ID: 37500379
[TBL] [Abstract][Full Text] [Related]
3. Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study.
Simon TA; Boers M; Hochberg M; Baker N; Skovron ML; Ray N; Singhal S; Suissa S; Gomez-Caminero A
Arthritis Res Ther; 2019 Nov; 21(1):228. PubMed ID: 31703717
[TBL] [Abstract][Full Text] [Related]
4. Abatacept and non-melanoma skin cancer in patients with rheumatoid arthritis: a comprehensive evaluation of randomised controlled trials and observational studies.
Simon TA; Dong L; Suissa S; Michaud K; Pedro S; Hochberg M; Boers M; Askling J; Frisell T; Strangfeld A; Meissner Y; Khaychuk V; Dominique A; Maldonado MA
Ann Rheum Dis; 2024 Jan; 83(2):177-183. PubMed ID: 37932010
[TBL] [Abstract][Full Text] [Related]
5. Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
Simon TA; Askling J; Lacaille D; Franklin J; Wolfe F; Covucci A; Suissa S; Hochberg MC;
Arthritis Res Ther; 2010; 12(2):R67. PubMed ID: 20398273
[TBL] [Abstract][Full Text] [Related]
6. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
Ozen G; Pedro S; Schumacher R; Simon TA; Michaud K
Arthritis Res Ther; 2019 Jun; 21(1):141. PubMed ID: 31174592
[TBL] [Abstract][Full Text] [Related]
7. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting.
Liang H; Danwada R; Guo D; Curtis JR; Kilpatrick RD; Hendrickson B; Islam SS
RMD Open; 2019; 5(2):e001013. PubMed ID: 31673413
[TBL] [Abstract][Full Text] [Related]
8. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries.
Dominique A; Hetland ML; Finckh A; Gottenberg JE; Iannone F; Caporali R; Kou TD; Nordstrom D; Hernandez MV; Sánchez-Piedra C; Sánchez-Alonso F; Pavelka K; Bond TC; Simon TA
Arthritis Res Ther; 2023 Jun; 25(1):101. PubMed ID: 37308978
[TBL] [Abstract][Full Text] [Related]
9. Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database.
Sattui SE; Navarro-Millan I; Xie F; Rajan M; Yun H; Curtis JR
Semin Arthritis Rheum; 2022 Dec; 57():152083. PubMed ID: 36155968
[TBL] [Abstract][Full Text] [Related]
10. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.
Grøn KL; Arkema EV; Glintborg B; Mehnert F; Østergaard M; Dreyer L; Nørgaard M; Krogh NS; Askling J; Hetland ML;
Ann Rheum Dis; 2019 Mar; 78(3):320-327. PubMed ID: 30612115
[TBL] [Abstract][Full Text] [Related]
12. Comparative safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with COPD: a real-world population study.
Hudson M; Dell'Aniello S; Shen S; Simon TA; Ernst P; Suissa S
Rheumatology (Oxford); 2020 Apr; 59(4):820-827. PubMed ID: 31504972
[TBL] [Abstract][Full Text] [Related]
13. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database.
Harigai M; Fujii T; Sakai R; Igarashi A; Shoji A; Yamaguchi H; Iwasaki K; Makishima M; Yoshida A; Okada N; Yamashita K; Kawahito Y
Mod Rheumatol; 2024 Feb; 34(2):287-296. PubMed ID: 37039670
[TBL] [Abstract][Full Text] [Related]
14. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
[TBL] [Abstract][Full Text] [Related]
15. Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs.
Baker MC; Liu Y; Lu R; Lin J; Melehani J; Robinson WH
JAMA Netw Open; 2023 Mar; 6(3):e233640. PubMed ID: 36939701
[TBL] [Abstract][Full Text] [Related]
16. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
17. Analysis of efficacy and safety of abatacept for rheumatoid arthritis: systematic review and meta-analysis.
Mohamed Ahamada M; Wu X
Clin Exp Rheumatol; 2023 Sep; 41(9):1882-1900. PubMed ID: 36912326
[TBL] [Abstract][Full Text] [Related]
18. Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice.
Huss V; Bower H; Wadström H; Frisell T; Askling J;
Rheumatology (Oxford); 2022 May; 61(5):1810-1818. PubMed ID: 34324640
[TBL] [Abstract][Full Text] [Related]
19. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.
Salmon JH; Gottenberg JE; Ravaud P; Cantagrel A; Combe B; Flipo RM; Schaeverbeke T; Houvenagel E; Gaudin P; Loeuille D; Rist S; Dougados M; Sibilia J; Le Loët X; Meyer O; Solau-Gervais E; Marcelli C; Bardin T; Pane I; Baron G; Perrodeau E; Mariette X;
Ann Rheum Dis; 2016 Jun; 75(6):1108-13. PubMed ID: 26048170
[TBL] [Abstract][Full Text] [Related]
20. Most Appropriate Conventional Disease-Modifying Antirheumatic Drug to Combine With Different Advanced Therapies in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.
Decarriere G; Barnetche T; Combe B; Gaujoux-Viala C; Lukas C; Morel J; Daien C
Arthritis Care Res (Hoboken); 2021 Jun; 73(6):873-884. PubMed ID: 32216091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]